Role of Oral Pre-exposure Prophylaxis (PrEP) in Current and Future HIV Prevention Strategies

被引：23

作者：

Burns, David N. ^{[1
]}

Grossman, Cynthia ^{[2
]}

Turpin, Jim ^{[1
]}

Elharrar, Vanessa ^{[1
]}

Veronese, Fulvia ^{[1
]}

机构：

[1] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA

[2] NIMH, Div Aids, NIH, Bethesda, MD 20892 USA

来源：

CURRENT HIV/AIDS REPORTS | 2014年 / 11卷 / 04期

关键词：

HIV/human immunodeficiency virus; Prevention; PrEP/pre-exposure prophylaxis; ARVs/antiretrovirals; UNITED-STATES; COST-EFFECTIVENESS; ANTIRETROVIRAL PROPHYLAXIS; TOPICAL MICROBICIDES; HETEROSEXUAL MEN; DRUG-RESISTANCE; SEX; INFECTION; TRANSMISSION; ADHERENCE;

D O I：

10.1007/s11904-014-0234-8

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Treatment as prevention is expected to have a major role in reducing HIV incidence, but other prevention interventions will also be required to bring the epidemic under control, particularly among key populations. One or more forms of pre-exposure prophylaxis (PrEP) will likely play a critical role. Oral PrEP with emtricitabine-tenofovir (TruvadaA (R)) is currently available in the US and some other countries, but uptake has been slow. We review the concerns that have contributed to this slow uptake and discuss current and future research in this critical area of HIV prevention research.

引用

页码：393 / 403

页数：11

共 81 条

[1] Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP) [J].